To assess whether adolescent isotretinoin treatment for acne is associated with reductions in adult height, specifically focusing on treatment during adolescence.
Key Findings:
Isotretinoin users had adjusted mean height differences of 0.3 cm among both men and women compared to the reference group, which is not clinically relevant.
Height differences remained below the predefined threshold of 5 cm for clinical relevance.
Cumulative isotretinoin exposure showed no dose-response association with adult height.
Stunting occurred in 1.5% of isotretinoin users compared to 2.1% in the reference group.
Interpretation:
The findings suggest that isotretinoin treatment during adolescence does not have a clinically meaningful impact on adult height.
Limitations:
The study was observational and exploratory beyond the primary hypothesis.
Lacked repeated height measurements and information on factors like pubertal timing and nutritional status.
Findings may not apply to high-dose isotretinoin regimens used for oncology or other conditions.
The potential impact of a healthy-user effect on the findings should be considered.
Conclusion:
The study provides reassurance regarding the impact of isotretinoin on adult height, supporting evidence-based decision-making for its use in adolescents, particularly for clinicians and patients.
From unexpected workplace parallels to kitchen-counter experiments and a few clinical twists, this set of stories covered more ground than your average shift.
